ERYTECH announces positive safety reviews after the completion of the first cohort in the company’s US Phase I study with eryaspase in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with eryaspase in combination with Folfox in its Phase II study in pancreatic cancer.
